Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Non-Current Assets (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Non-Current Assets for 4 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 11.08% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, down 17.73% year-over-year, with the annual reading at $3.4 million for FY2025, 11.08% down from the prior year.
  • Non-Current Assets for Q4 2025 was $3.4 million at bioAffinity Technologies, up from $2.9 million in the prior quarter.
  • The five-year high for Non-Current Assets was $4.2 million in Q4 2023, with the low at $7781.0 in Q3 2022.
  • Average Non-Current Assets over 4 years is $2.7 million, with a median of $3.5 million recorded in 2025.
  • The sharpest move saw Non-Current Assets surged 53611.03% in 2023, then fell 26.73% in 2025.
  • Over 4 years, Non-Current Assets stood at $220438.0 in 2022, then soared by 1827.44% to $4.2 million in 2023, then dropped by 10.13% to $3.8 million in 2024, then fell by 11.08% to $3.4 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $3.4 million, $2.9 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.